The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered across the U.S. Thus far, only the sites in Florida and Utah are open for enrollment; more information can be found here. The remaining sites are in high COVID-19 areas and…
You must be logged in to read/download the full post.
The post First Patients Dosed in Annovis Bio’s ANVS401 Trial, Delayed Due to COVID-19 appeared first on BioNewsFeeds.